Pyoderma gangrenosum
Pyoderma gangrenosum አልፎ አልፎ የሚያቃጥል የቆዳ በሽታ ሲሆን የሚያሰቃዩ የ pustules ወይም nodules ቀስ በቀስ የሚያድግ ቁስለት ይሆናሉ። pyoderma gangrenosum ተላላፊ አይደለም። ሕክምናዎች ኮርቲኮስትሮይድ፣ ሳይክሎፖሮን ወይም የተለያዩ ሞኖክሎናል ፀረ እንግዳ አካላትን ሊያካትቱ ይችላሉ። ምንም እንኳን በማንኛውም እድሜ ላይ ያሉ ሰዎችን ሊጎዳ ቢችልም, በአብዛኛው በ 40 ዎቹ እና በ 50 ዎቹ ውስጥ ያሉ ሰዎችን ይጎዳል.
☆ እ.ኤ.አ. በ 2022 ከጀርመን የስቲፍቱንግ ዋረንቴስት ውጤቶች ፣ በሞዴልደርም የተገልጋዮች እርካታ ከሚከፈልባቸው የቴሌሜዲኬን ምክሮች በትንሹ ያነሰ ነበር።
አልሰርቲቭ ኮላይትስ ያለበት ሰው እግር ላይ።
References
Pyoderma gangrenosum ብርቅዬ የቆዳ በሽታ ሲሆን በቀይ ወይም በነጭ ጠርዝ ላይ የሚያሰቃይ ቁስለት ያስከትላል። እንደ ኢንፍላማቶሪ በሽታ ተመድቧል እና ኒውትሮፊል dermatosis የተባለ ቡድን አካል ነው። የ pyoderma gangrenosum መንስኤ ውስብስብ ነው፣ በጄኔቲክ ተጋላጭ በሆኑ ሰዎች ላይ በተፈጥሮም ሆነ በተለዋዋጭ የበሽታ መከላከል ላይ ያሉ ችግሮችን ያካትታል። በቅርቡ ተመራማሪዎች የበሽታው መነሻ ሊሆኑ የሚችሉ የፀጉር መርገጫዎች ላይ ትኩረት አድርገዋል.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum በጣም አልፎ አልፎ የሚከሰት የቆዳ ህመም እጅግ በጣም የሚያም ቁስለት ነው። መንስኤውን ሙሉ በሙሉ ባንረዳም፣ የተወሰኑ የበሽታ ተከላካይ ሕዋሳት እንቅስቃሴን እንደሚጨምር እናውቃለን። በሽታውን ማከም አሁንም ቀላል አይደለም. በሽታ የመከላከል ስርዓትን የሚቀንሱ ወይም እንቅስቃሴውን የሚያሻሽሉ የተለያዩ መድሃኒቶች አሉን. ከነዚህ ጎን ለጎን ቁስሎችን በማከም እና ህመምን በመቆጣጠር ላይ እናተኩራለን. Corticosteroids እና cyclosporine ብዙውን ጊዜ ለህክምና የመጀመሪያ ምርጫዎች ናቸው, ነገር ግን ከቅርብ ጊዜ ወዲህ እንደ TNF-α አጋቾቹ ያሉ ባዮሎጂያዊ ሕክምናዎችን ስለመጠቀም ተጨማሪ ጥናቶች ተካሂደዋል. እነዚህ ባዮሎጂስቶች እየጨመረ የሚሄዱ ናቸው, በተለይም ሌሎች የሚያነቃቁ ሁኔታዎች ባለባቸው ታካሚዎች, እና በበሽታው ሂደት ውስጥ ቀደም ብለው ጥቅም ላይ ይውላሉ.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
